These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23945251)

  • 21. Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics.
    Chandasana H; Hayes S; Buchanan AM; Brothers C; Wiznia A; Bartlett M; Popson S; Townley E; George K; Vavro C; Ruel T; Acosta EP; Singh R;
    AIDS; 2024 Jul; 38(9):F11-F18. PubMed ID: 38768443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
    Yamada E; Takagi R; Moro H; Sudo K; Kato S
    PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
    Elliot E; Amara A; Jackson A; Moyle G; Else L; Khoo S; Back D; Owen A; Boffito M
    J Antimicrob Chemother; 2016 Apr; 71(4):1031-6. PubMed ID: 26679246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Patel P; Wajima T; Peppercorn A; Piscitelli SC
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1627-9. PubMed ID: 22183173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.
    Cottrell ML; Hadzic T; Kashuba AD
    Clin Pharmacokinet; 2013 Nov; 52(11):981-94. PubMed ID: 23824675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition.
    Elliot ER; Wang X; Singh S; Simmons B; Vera JH; Miller RF; Fitzpatrick C; Moyle G; McClure M; Boffito M
    Clin Infect Dis; 2019 Jan; 68(1):87-95. PubMed ID: 29771285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Creation of a long-acting nanoformulated dolutegravir.
    Sillman B; Bade AN; Dash PK; Bhargavan B; Kocher T; Mathews S; Su H; Kanmogne GD; Poluektova LY; Gorantla S; McMillan J; Gautam N; Alnouti Y; Edagwa B; Gendelman HE
    Nat Commun; 2018 Feb; 9(1):443. PubMed ID: 29402886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
    Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR
    Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.
    Viani RM; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Steimers D; Min S; Wiznia A;
    Pediatr Infect Dis J; 2015 Nov; 34(11):1207-13. PubMed ID: 26244832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
    Johnson M; Borland J; Chen S; Savina P; Wynne B; Piscitelli S
    Br J Clin Pharmacol; 2014 Nov; 78(5):1043-9. PubMed ID: 24838177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Chronic Dolutegravir Administration on the Trace Amine Profile in Wistar Rats.
    Henning N; Kellermann TA; Smith C
    Drugs R D; 2024 Sep; 24(3):435-445. PubMed ID: 39177936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.
    Castellino S; Moss L; Wagner D; Borland J; Song I; Chen S; Lou Y; Min SS; Goljer I; Culp A; Piscitelli SC; Savina PM
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3536-46. PubMed ID: 23669385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.
    MacBrayne CE; Castillo-Mancilla J; Burton JR; MaWhinney S; Wagner CB; Micke K; Fey J; Huntley RT; Larson B; Bushman LR; Kiser JJ
    J Antimicrob Chemother; 2018 Jan; 73(1):156-159. PubMed ID: 29029135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
    Ross LL; Song IH; Arya N; Choukour M; Zong J; Huang SP; Eley T; Wynne B; Buchanan AM
    BMC Infect Dis; 2016 Jul; 16():347. PubMed ID: 27450277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.
    Dooley KE; Sayre P; Borland J; Purdy E; Chen S; Song I; Peppercorn A; Everts S; Piscitelli S; Flexner C
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):21-7. PubMed ID: 23075918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults.
    Buchanan AM; Holton M; Conn I; Davies M; Choukour M; Wynne BR
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):577-583. PubMed ID: 28168828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1.
    Yagura H; Watanabe D; Kushida H; Tomishima K; Togami H; Hirano A; Takahashi M; Hirota K; Ikuma M; Kasai D; Nishida Y; Yoshino M; Yamazaki K; Uehira T; Shirasaka T
    BMC Infect Dis; 2017 Sep; 17(1):622. PubMed ID: 28915895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
    Cid-Silva P; Llibre JM; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Pernas-Souto B; Martín-Herranz I; Castro-Iglesias Á; Poveda E
    Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):442-446. PubMed ID: 28627771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.
    Brown KC; Patterson KB; Jennings SH; Malone SA; Shaheen NJ; Asher Prince HM; Spacek M; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):138-44. PubMed ID: 22614898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.